检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:赵海燕[1] 吴寿岭[1] 孙立霞[2] 李云[1] 侯国盛[1] 刘福山[1] 王黎光[1] 吴云涛[1]
机构地区:[1]华北煤炭医学院附属开滦医院心内科,河北唐山063000 [2]唐山市协和医院急诊科,河北唐山063000
出 处:《高血压杂志》2006年第1期23-27,共5页Chinese Journal of Hypertension
摘 要:目的评价小剂量氢氯噻嗪(HCTZ)与螺内酯、卡托普利联用的降压疗效和安全性。方法采用多中心、随机、双盲、平行对照试验,选择轻中度高血压患者829例,经2周安慰剂洗脱期、6周HCTZ导入期后随机进入HCTZ12.5mg q.d组HCTZ12·5mg与螺内酯20mg q.d组HCTZ12·5mg q.d与卡托普利25mg b.i.d组治疗,共12个月,随访1次/月。治疗前、治疗6周末和治疗12个月末分别进行血生化检查并评估降压疗效及安全性。结果①治疗6周末,3组的坐位收缩压及舒张压(以下血压值均指坐位血压值)较治疗前明显下降(P<0·01,P<0·01)。治疗12个月末3组的血压值仍明显下降。HCTZ组、螺内酯组和卡托普利组患者的收缩压下降值分别为(10·5±17·3),(13·3±15·8),(14·6±17·4)mmHg,卡托普利组下降幅度较HCTZ组明显(P=0·034)。②HCTZ组、螺内酯组和卡托普利组降压达标率分别为34·9%、44·3%和47·1%,HCTZ组达标率低于其他两组(44·3%vs34·9%P=0·038;47·1%vs34·9%P<0·001),螺内酯和卡托普利2组间无统计学差异。③3组间副反应发生率无统计学差异。结论小剂量HCTZ与螺内酯、卡托普利联用降压安全有效。Objective To study the antihypertensive effects of low-dose hydrochlorothiazide (HCTZ) in combination with Captopril or Spironolactone in mild or moderate hypertensive patients. Methods A muhicenter, randomized, double blind, actively-controlled clinical trial was conducted. After two weeks' washout period and 6 weeks' leading period, 829 patients were randomized to receive HCTZ (12.5 mg, q. d)group or HCTZ(12. 5 mg q. d)/Spironolactone(20 mg q.d) group or HCTZ(12. 5 mg q. d)/Captopril (25 mg b. i. d) group for 12 months. Results ①After 6 weeks of treatment, blood pressure (BP) was significantly reduced in all groups (P〈0.01, respectively). After 12 months of treatment, therapeutic effect was sustained and SBP was decreased more markedly in the HCTZ /Captopril group than that in other groups [(14.6±17.4 vs HCTZ 10.5±17.3, P=0. 027; 14. 6±17.4 vs HCTZ/ Spri 13.3± 15.8)mm Hg, P〉0.05]. ②The response rate in HCTZ/Spironolactone or HCTZ/Captopril group were higher than HCTZ group [44.3% vs 34.9%, P=0.038; 47.1% vs 34.9%, P〈0. 001). ③ Adverse effects among three groups were comparable (P〉0.05). Conclusion The low-dose HCTZ in combination with captopril or spironolactone is effective and safe for patients with essential hypertension.
分 类 号:R544.1[医药卫生—心血管疾病] R972.4[医药卫生—内科学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222